Search Results
Your search for ,itS matches 8761 pages
Showing 5151 - 5200ICML 2017: Phase III GENUINE Trial: Ublituximab Plus Ibrutinib in High-Risk CLL
Data was recently presented from the phase III GENUINE trial of ublituximab, a novel glycoengineered anti–CD20 monoclonal antibody, in combination with ibrutinib (Imbruvica), a Bruton tyrosine kinase (BTK) inhibitor, for the treatment of high-risk chronic lymphocytic leukemia (CLL), at the...
ICML 2017: Phase II Trial of Tazemetostat in Relapsed or Refractory Follicular Lymphoma and DLBCL
Positive interim efficacy data from an ongoing phase II clinical trial of tazemetostat, a first-in-class, oral enhancer of zeste homolog 2 (EZH2) inhibitor, as a single-agent treatment for relapsed or refractory patients with follicular lymphoma or diffuse large B-cell lymphoma (DLBCL) grouped by...
AACR Publishes First Set of Screening Recommendations Emerging From Childhood Cancer Predisposition Workshop
The American Association for Cancer Research (AACR) has published its first set of consensus screening recommendations for children with common cancer predisposition syndromes in Clinical Cancer Research. These recommendations emerged from the Childhood Cancer Predisposition Workshop held by the...
First Analysis of AACR Project GENIE Data Published
The first analysis of nearly 19,000 de-identified genomic records from the American Association for Cancer Research (AACR) international data-sharing initiative known as AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE) was recently published in Cancer Discovery. In addition to ...
ASCO 2017: SWOG Clinical Trials Have Added More Than 3 Million Years of Life for Patients With Cancer
For an investment of $125 for each year of life gained since the 1950s, the National Cancer Institute (NCI)-funded SWOG clinical trials program has added 3.34 million years of life for patients with cancer in the United States because of successful therapies that were proved through its trials....
Memorial Sloan Kettering Cancer Center’s ‘Visible Ink’ Writing Program Gives Voice to the Experiences of Cancer Survivors
On April 3, 2017, Memorial Sloan Kettering Cancer Center (MSKCC) in New York celebrated its ninth year of live performances of the cancer experience written by survivors participating in the center’s Visible Ink writing program. The evening’s performances were the culmination of months-long...
Cancer Has Made Me a Better Person
Eight years ago, I was on top of the world. I had moved to Los Angeles, California, in 2007, from my home in Poços de Caldas, Brazil, to pursue my dream of launching a singing career in the United States, and was finally making progress. I had just completed composing songs for my debut album and...
Fred & Pamela Buffett Cancer Center Dedicated at UNMC
The University of Nebraska Medical Center (UNMC) and its clinical partner, Nebraska Medicine, has officially dedicated the new Fred & Pamela Buffett Cancer Center in Omaha. Joe Biden, the former two-term Vice President who headed a national Cancer Moonshot Task Force, served as keynote speaker...
Brian Wolpin, MD, MPH, Named Director of Gastrointestinal Cancer Center at Dana-Farber
Brian Wolpin, MD, MPH, has been named the new Director of the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute. Dr. Wolpin is Associate Professor of Medicine at Harvard Medical School and was appointed earlier this year as the Robert T. and Judith B. Hale Chair in Pancreatic Cancer...
Geriatric Oncology: A Multidisciplinary Approach in a Global Environment
Geriatrics for the Oncologist is guest edited by Stuart M. Lichtman, MD, FACP, FASCO, and developed in collaboration with the International Society of Geriatric Oncology (SIOG). Dr. Lichtman is an Attending Physician at Memorial Sloan Kettering Cancer Center, Commack, New York, and Professor of...
ASCO COME HOME Offers Direct Support to Practices Transitioning to Quality Payment Program
ASCO is making it easier for practices to understand and prepare for the transition to the Quality Payment Program (QPP) in the years ahead with its ASCO COME HOME initiative. ASCO COME HOME provides readiness assessment tools to help practices evaluate whether or not they are ready to transition...
Wendy S. Rubinstein, MD, PhD, FACMG, FACP, Joins CancerLinQ LLC as Division Director, Clinical Data Management and Curation
CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, has -announced that Wendy S. Rubinstein, MD, PhD, FACMG, FACP, will be its first Division Director, Clinical Data Management and Curation. Dr. Rubinstein will oversee the team working to securely process and analyze the -CancerLinQ®...
Combination Therapy With Pembrolizumab in Metastatic Nonsquamous NSCLC
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On May 10, 2017, pembrolizumab (Keytruda) was granted accelerated...
Optimizing Quality of Life in Head and Neck Cancer Survivors
Head and neck cancer can take away a patient’s “right to feel human,” and its impact on physical appearance, physical functioning, and general quality of life can be devastating, according to Merry Sebelik, MD, Associate Professor of Head and Neck Surgery at Emory University in Atlanta. At a...
Proton Therapy Associated With Fewer Sequelae in the Treatment of Head and Neck Cancer
Radiation oncology is vital to the management of patients with cancer of the head and neck, and for certain patients, proton therapy may offer significant benefit over intensity-modulated radiation therapy, according to Walter J. Curran, MD, Executive Director of the Winship Cancer Institute of...
Targeted Therapy in the Age of Immunotherapy in Head and Neck Cancer
The impact of targeted therapies in head and neck cancer has been limited, but we can strategize to integrate the development of targeted and immunotherapeutic agents, according to Christine H. Chung, MD, Senior Member and Chair in the Department of Head and Neck-Endocrine Oncology at Moffitt...
New Horizons in Immunotherapy for Head and Neck Cancer
Immunotherapy is a new treatment paradigm in recurrent metastatic head and neck cancer, according to Nabil F. Saba, MD. At a symposium hosted by the Winship Cancer Institute and Emory University—Updates in the Management of Head and Neck Cancer—Dr. Saba discussed current research and new...
Idelalisib Toxicities Appear to Be Immune-Related
Phosphoinositide 3-kinase (PI3K) inhibitors represent a highly active class of drug for the treatment of chronic lymphocytic leukemia (CLL). Idelalisib (Zydelig), a PI3K-delta inhibitor and the first PI3K inhibitor to be approved by the U.S. Food and Drug Administration (FDA) for CLL, has...
Making American Research Great Again
In the past 10 years, we have made remarkable advances in how we fight cancer. One of the most powerful new tools in our arsenal is cancer immunotherapy, which reawakens our own immune system to produce stunning results for many suffering from advanced cancer. Immunotherapy saved President Jimmy...
FDA Requests Removal of Oxymorphone Hydrochloride for Risks Related to Abuse
On June 8,the U.S. Food and Drug Administration (FDA) requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated oxymorphone hydrochloride (Opana ER), from the market. After careful consideration, the agency is seeking removal based on its concern that the benefits of the...
ASCO 2017: Ibrutinib Plus Cellular Therapy CTL119 May Lead to Complete Remissions in CLL
Combining the kinase inhibitor ibrutinib (Imbruvica) with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman School of Medicine at the University...
Value-Based Decision-Making Tools: The View Ahead
As new treatment decision-making tools make their way toward and into the clinic, oncologists are getting a sense of how they may affect clinical practice—and beginning to look farther down the road. “What do you see ahead for clinicians?” asked Christian Downs, JD, Executive Director of the...
ASCO 2017: Higher Gut Bacteria Diversity Tied to Slower Metastatic Melanoma Progression
The blend of bacteria in the digestive tract of metastatic melanoma patients is associated with disease progression or delay in patients treated with immunotherapy, reported Wargo et al at the 2017 ASCO Annual Meeting (Abstract 3008). Their study of fecal samples from 105 patients treated with...
ASCO 2017: Adding PEGPH20 to Standard Treatment in Metastatic Pancreatic Cancer May Delay Disease Progression
By adding an experimental drug to a standard chemotherapy regimen, a subset of patients with metastatic pancreatic cancer had a significantly longer period before the cancer progressed as compared with those who received the standard treatment, according to a phase II clinical trial led by an...
ASCO 2017: Implementing Cost Transparency in Oncology
Being transparent about the cost of cancer treatments with patients has been increasingly recommended to help minimize financial harm and improve care, but what's preventing or derailing those conversations is less understood. New findings from Penn Medicine that identified several barriers and key ...
ASCO's TAPUR Study Continues Its Expansion of Sites, Participants, and Collaborators
ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study continues to expand and now has more than 300 participants enrolled on study drug, more than 100 sites, new partnerships, and a revised protocol to lower the age of eligibility. “We are very pleased with the...
ASCO 2017: Research Suggests Possible New Treatment for EGFR-Positive Lung Cancer
Findings from a phase III clinical trial point to a potential new treatment for patients newly diagnosed with advanced, epidermal growth factor receptor (EGFR)-positive non–small cell lung cancer (NSCLC). Compared to the EGFR inhibitor gefitinib (Iressa), one of the standard targeted...
ASCO 2017: Early Research Suggests First Immunotherapy for Mesothelioma on the Horizon
Malignant pleural mesothelioma is a rare cancer, but its incidence has been rising. This cancer is usually associated with asbestos exposure, and patients have a median life expectancy of only 13 to 15 months. All patients relapse despite initial chemotherapy, more than 50% of them within 6 months...
ASCO 2017: The IDEA Collaboration: Global Study Sets New Risk-Based Standard to Personalize Chemotherapy for Colon Cancer After Surgery
After surgery for lymph node–positive colon cancer (stage III), some patients may need only half of the long-standing standard course of chemotherapy. In an analysis of 6 clinical trials with over 12,800 patients, 3 months of chemotherapy was nearly as effective as 6 months in patients with...
ASCO 2017: OlympiAD Trial: Olaparib Slows Growth of BRCA-Related Metastatic Breast Cancer
Findings from a phase III clinical trial of about 300 women may introduce poly ADP ribose polymerase (PARP) inhibitors as a new type of treatment for breast cancer. Compared to standard chemotherapy, the oral targeted medicine olaparib (Lynparza) reduced the chance of progression of advanced,...
ASCO 2017: ProfiLER Trial: Routine Genomic Testing Feasible, but Only a Subset of Patients May Benefit
Genomic testing of tumor samples can enable personalized treatment selection, where targeted treatments are matched to genetic changes in the tumor. Although a growing number of patients with advanced cancers receive some genomic testing, comprehensive genomic testing is not yet routine care. A...
ASCO 2017: Low Testosterone Level After Testicular Cancer Is Common, Linked to Chronic Health Problems
In a large study, 38% of 491 testicular cancer survivors had low testosterone levels. Compared with survivors with normal testosterone levels, survivors with low testosterone levels were more likely to have a range of chronic health problems, including high blood pressure, diabetes, erectile...
ASCO 2017: CALM Intervention Relieves Distress in Patients With Advanced Cancer
Advanced cancer triggers enormous distress and brings challenges that can seem overwhelming. Yet most cancer centers lack systematic approaches to help patients and families manage the practical and emotional toll of advanced cancer. Findings from a randomized clinical trial of 305 patients with...
ASCO Announces CancerLinQ Partnerships With the FDA and the NCI
CancerLinQ®, ASCO’s big data initiative to rapidly improve the quality of cancer care, is partnering with the U.S. Food and Drug Administration (FDA) and the National Cancer Institute (NCI) to study the real-world use of newly approved cancer treatments and speed and strengthen the...
Image-Guided Biopsies Accurately Identify Patients With Breast Cancer Who Achieve Pathologic Complete Response Following Neoadjuvant Therapy
In a clinical feasibility trial conducted at The University of Texas MD Anderson Cancer Center, image-guided biopsies identified select breast cancer patients who achieved pathologic complete response after neoadjuvant systemic therapy consisting of chemotherapy and/or targeted therapy. Should the...
After Nearly 4 Decades of Research, W.K. Alfred Yung, MD, Sees a New Era Ahead for Advances in Brain Tumors
After he was not accepted into the University of Hong Kong, plan B for W.K. Alfred Yung, MD, was to leave his country and immigrate to the United States to attend the University of Minnesota in Minneapolis—a move he considers more exile than choice. Born on April 8, 1948, in Hong Kong, Dr. Yung...
Conquer Cancer Foundation of ASCO Awards Celebrate Innovation and Diversity
The Conquer Cancer Foundation of ASCO (CCF) is proud to recognize the recipients of its 2017 CCF Merit Awards and its Diversity Awards, which include the Medical Student Rotation Award for Underrepresented Populations and the Resident Travel Award for Underrepresented Populations. Geared toward...
Eliezer Robinson, MD, Traveled a Long, Hard Road and Became an International Leader in Oncology
Eliezer Robinson, MD, was born in Vienna, Austria, on June 17, 1931. At that time, Vienna, a bustling and prosperous city, was an important center of Jewish culture and education. Jews made up a large portion of the city’s professional class of doctors, lawyers, bankers, and artists. Dr. Robinson...
Scott Gottlieb, MD, Receives Confirmation as FDA Commissioner
Statement by 2016–2017 ASCO President Daniel F. Hayes, MD, FACP, FASCO: “The American Society of Clinical Oncology (ASCO) congratulates Scott Gottlieb, MD, on his confirmation as Commissioner of the U.S. Food and Drug Administration (FDA). With more than 1.7 million new cancer diagnoses made in...
Radiation Oncologist Lori J. Pierce, MD, FASCO, FASTRO, Enjoys Balancing Administrative and Clinical Roles
Lori J. Pierce, MD, FASCO, FASTRO, grew up in Washington, DC, and moved with her family to Philadelphia while in high school. She still considers the fast-paced DC–Philadelphia corridor her home, but her passion for a career in medicine, in part, took seed in a small town located in North...
Special Awards and Lectures Presented During 2017 ASCO Annual Meeting
Recipients of ASCO’s Notable Awards and Lectures are individuals who have made extraordinary contributions to the research and treatment of patients with cancer. These individuals were honored during several special sessions held during ASCO’s 53rd Annual Meeting, where more than 30,000 physicians, ...
Robert Vonderheide, MD, DPhil, Named Director of Abramson Cancer Center
Robert Vonderheide, MD, DPhil, has been named the new Director of the Abramson Cancer Center (ACC) of the University of Pennsylvania. He is the Hanna Wise Professor in Cancer Research at the Perelman School of Medicine and currently serves as the ACC’s Associate Director for Translational Research ...
Distinguished Pediatric Oncologist Anna T. Meadows, MD, Led the Way for Studies in Childhood Cancer Survivors
Anna T. Meadows, MD, an internationally distinguished pediatric oncologist who led paradigm-changing survivorship research and clinical care of children with cancer, had an unusual introduction to the United States. “My mother was traveling abroad on vacation and got married in Poland. Although...
Clinical Researcher George P. Canellos, MD, Closely Involved With Two of the Most Influential Treatments in Cancer Care
George P. Canellos, MD, President of ASCO from 1993 to 1994, was born in Boston on November 1, 1934. “I came from a business family and never wanted to do business at all. As long back as I can remember, I always found medicine attractive—not only because you could help people, but you could also...
Daniel Von Hoff, MD, FACP, Receives Gold Medal From Columbia University
Daniel Von Hoff, MD, FACP—Distinguished Professor, Physician-in-Chief, and Director of Molecular Medicine at the Translational Genomics Research Institute—received a gold medal for excellence in clinical medicine from his alma mater, Columbia University. Columbia University College of Physicians...
Nobel Prize in Physiology or Medicine: Laureates in Oncology
The Nobel Prize in Physiology or Medicine has been awarded to many individuals whose research directly impacted the understanding of cancer: In 2008 to Harald zur Hausen, for his discovery of human papillomavirus causing cervical cancer In 2005 to J. Robin Warren and Barry J. Marshall, for their...
Nobel Laureate David Baltimore, PhD, Plays Integral Role in Linking Cell Biology and Cancer Genetics
David Baltimore, PhD, whose work profoundly influenced international science, was born on March 7, 1938, in Queens, New York, to Gertrude and Richard Baltimore. While he was in second grade, the family moved to Great Neck, New York, a middle-class suburb with top-notch public schools. “My father...
ASCO President, Bruce E. Johnson, MD, FASCO, Participates in Key Research With EGFR Mutation in Lung Cancer
Bruce E. Johnson, MD, FASCO, 2017–2018 ASCO President, was born in St. Peter, Minnesota, and grew up on a rural dairy farm. “Neither of my parents had college degrees, but working on a dairy farm with them gave me a solid work ethic. I was working outside on the farm before I was 10 years old. In...
OPTIMIZE-2 Trial Offers Reassuring Data on Deescalation of Bisphosphonate Therapy for Breast Cancer–Related Bone Metastases
Bisphosphonates were first synthesized more than a century ago, with their initial usage restricted to a range of industrial processes until their potential clinical relevance was appreciated in the late 1960s.1 Then, following development for the treatment of osteoporosis and Paget’s disease of...
Weight Management and Physical Activity in Cancer Care: From Research to Real World
Is there enough evidence to support the incorporation of weight management and physical activity interventions into an oncology practice? And if so, what is the best way to do it? The answer to the first question was a resounding yes from oncologists, patient advocates, dietitians, public health...
